<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915928</url>
  </required_header>
  <id_info>
    <org_study_id>Chronic Subdural Hematoma</org_study_id>
    <secondary_id>Eudra CT nummer 2009-010058-37</secondary_id>
    <nct_id>NCT00915928</nct_id>
  </id_info>
  <brief_title>Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors</brief_title>
  <acronym>KSDH</acronym>
  <official_title>Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alice Brenaa Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hede Nielsen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Overlægerådets legatudvalg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project aims at investigating if treatment with the Angiotensin Converting Enzyme&#xD;
      inhibitor Coversyl (perindopril) for 3 months after surgery for chronic subdural hematoma&#xD;
      will decrease the risc of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have indicated that treatment with ACE inhibitors can reduce the risk of&#xD;
      recurrence of CSDH after surgical evacuation. This randomized clinical trial was designed to&#xD;
      investigate this&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No effect of the ACE inhibitor evaluated halfway in the study&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of Chronic Subdural Hematoma (CSDH)</measure>
    <time_frame>3 months</time_frame>
    <description>Volume of CSDH remnant three months after evacuation measure using xyz/2 on CT scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composition of Chronic Subdural Hematoma Fluid</measure>
    <time_frame>years</time_frame>
    <description>Post-Hoc Outcome Measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hematoma, Subdural, Chronic</condition>
  <arm_group>
    <arm_group_label>ACE inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients randomized to this arm will be treated with ACE inhibitors after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients randomized to this arm will be treated with placebo after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>2,5 mg daily for 3 months</description>
    <arm_group_label>ACE inhibitor</arm_group_label>
    <other_name>coversyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dayli for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with chronic subdural hematoma that needs surgical evacuation&#xD;
&#xD;
          2. Age &gt; 18 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of compliance&#xD;
&#xD;
          2. Kidney artery stenosis&#xD;
&#xD;
          3. Stenosis of the aorta&#xD;
&#xD;
          4. Severely decreased kidney function&#xD;
&#xD;
          5. Allergy or intolerance/contraindications toward ACE inhibitors&#xD;
&#xD;
          6. Already in ACE inhibitor treatment&#xD;
&#xD;
          7. Coagulopathies&#xD;
&#xD;
          8. Malignant disorders&#xD;
&#xD;
          9. Fertile women&#xD;
&#xD;
         10. Other neurological disorders&#xD;
&#xD;
         11. Treatment with pharmaceuticals contraindicating treatment with ACE inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frantz R Poulsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Odense University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <results_first_submitted>August 14, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Frantz Rom Poulsen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Neurosurgical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ACE Inhibitor</title>
          <description>Perindopril: 2,5 mg daily for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with CSDH and indication for surgery. Either male or female</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>three months placebo treatment after surgical CSDH evacuation</description>
        </group>
        <group group_id="B2">
          <title>Perindopril</title>
          <description>three months perindopril treatment after surgical CSDH evacuation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="5"/>
                    <measurement group_id="B2" value="64.3" spread="5"/>
                    <measurement group_id="B3" value="67.2" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>CSDH and indication for surgical evacuation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Prospective, randomized</description>
          <population>Many patients were not able to consent and the neurosurgeon on call were too busy to include in the project</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Size of Chronic Subdural Hematoma</title>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130" spread="10"/>
                    <measurement group_id="B2" value="124" spread="10"/>
                    <measurement group_id="B3" value="127" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Size of Chronic Subdural Hematoma (CSDH)</title>
        <description>Volume of CSDH remnant three months after evacuation measure using xyz/2 on CT scans</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE Inhibitor</title>
            <description>Perindopril: 2,5 mg daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Chronic Subdural Hematoma (CSDH)</title>
          <description>Volume of CSDH remnant three months after evacuation measure using xyz/2 on CT scans</description>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="5"/>
                    <measurement group_id="O2" value="22.8" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composition of Chronic Subdural Hematoma Fluid</title>
        <description>Post-Hoc Outcome Measure</description>
        <time_frame>years</time_frame>
        <population>Analysis will not be performed due to insufficient funding and the samples will be destroyed</population>
        <group_list>
          <group group_id="O1">
            <title>Composition of Chronic Subdural Hematoma Fluid</title>
            <description>Biochemical analysis of CSDH fluid content. This analysis will not be performed due to insufficient funding</description>
          </group>
        </group_list>
        <measure>
          <title>Composition of Chronic Subdural Hematoma Fluid</title>
          <description>Post-Hoc Outcome Measure</description>
          <population>Analysis will not be performed due to insufficient funding and the samples will be destroyed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Low dose of a well tolerated and well known drug in the active drug arm</desc>
      <group_list>
        <group group_id="E1">
          <title>ACE Inhibitor</title>
          <description>Active compound</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Inactive placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frantz Rom Poulsen, Professor, consultant</name_or_title>
      <organization>Odense University Hospital, Odense, Denmark</organization>
      <phone>0045 65413600</phone>
      <email>frantz.r.poulsen@rsyd.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

